Cancer after Lymphoma - take past results with open eyes and a sun hat
An April study in the Journal of Clinical Oncology looked at the risk of second cancers after Non-Hodgkin's lymphoma. If you or a loved one were treated between 1973 and 2000, this may be of interest.
BUT . . .
If treatment was recent, such a study may be nearly useless and might impart the wrong information. Newer treatments for NHL have improved remission rates and chances are that new trial drugs will continue to lead to better treatments. Thus studying the past does not have any correlation with how current patients may do.
The mainstream media picked up this study and wrote articles - I'm afraid people may get the wrong information if treated from 2000 on. Remember - if you question something, dig deeper and ask the doctors.
Of course, you might get a second cancer like I did (basil cell carcinoma) - my suggestion: have it removed from your skin, stay out of direct sun and wear sunblock when appropriate :-)
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
